Clinical trials: Type A Botulinum Toxin
Platysma Prominence
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.
- Trial name
- NCT04994535
- Testing
- OnabotulinumtoxinA
- Where
- 34 sites in United States, Belgium and 3 more
- Volunteers
- 426 people
- Sponsor
- AbbVie
Stroke With Hemiparesis
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
The purpose of this study is to determine whether injections of botulinum toxin (commonly known as BOTOX®) into the affected hand of Stroke patients, while targeting the muscles controlling the hand, will lead to improved use of…
- Trial name
- NCT01422161
- Testing
- Botulinum Toxin commonly known as BOTOX®
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NYU Langone Health
Restless Legs Syndrome
Botulinum Toxin to Treat Restless Legs Syndrome
This study will test whether botulinum toxin (Botox) may relieve the uncomfortable sensations patients with restless legs syndrome (RLS) experience.
- Trial name
- NCT00479154
- Testing
- Botulinum Toxin A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Stroke (CVA) or TIA, Headache, Migraine
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
Post stroke headache occurs in approximately 10-23% of all stroke patients. Its onset is shortly after experiencing a stroke, or stroke like event, and persists for at least three months.
- Conditions
- Stroke (CVA) or TIA, Headache, Migraine, Botulinum Toxins, Type A, Cerebral Venous Sinus Thrombosis
- Trial name
- NCT04580238
- Testing
- Botox 200 UNT Injection, Non Botox based Standard of Care Treatments for Headache/Migraine
- Where
- Canada
- Sponsor
- University of Alberta
Sialorrhea, Cerebral Palsy
Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy
The purpose of this study is to evaluate the safety and efficacy of botulinum toxin-A in salivary glands as a treatment for decrease drooling in patients with cerebral palsy and evaluate the long-term effects and tolerance .
- Trial name
- NCT01489904
- Testing
- BOTULINUM NEUROTOXIN TYPE-A
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Vall d'Hebron
Lower Limb Spasticity Due to Cerebral Palsy
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle…
- Trial name
- NCT01893411
- Testing
- IncobotulinumtoxinA (16 Units per kg body weight), IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight)
- Where
- 53 sites in Austria, Czechia and 12 more
- Volunteers
- 311 people
- Sponsor
- Merz Pharmaceuticals GmbH
Acne Vulgaris
Clinical Trial To Evaluate ANT-1207 In Subjects With Acne
The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of acne.
- Trial name
- NCT01293552
- Testing
- ANT-1207, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 72 people
- Sponsor
- Anterios Inc.
Stroke
The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke
The aim of this study is to determine whether early use of OnabotulinumtoxinA is more effective to improve functional outcomes of upper limb in patients with stroke.
- Trial name
- NCT02580838
- Testing
- OnabotulinumtoxinA
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Cheng-Kung University Hospital
Blepharospasm
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
To compare the efficacy and safety of Korean botulinum toxin A (KbtxA, Pacific Pharmaceuticals, Korea) against Botox in the treatment of essential blepharospasm, we performed a double-blinded, randomized, comparative trial…
- Trial name
- NCT00682760
- Testing
- Korean Botulinum toxin type A (KbtxA) and Botox injection
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Pacific Pharmaceuticals
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Spasticity
Vanderbilt University Spasticity Management Program Evaluation Plan
People with severe developmental disabilities frequently have comorbidities that make providing care to them more difficult. Spasticity is one such comorbidity.
- Trial name
- NCT00179114
- Testing
- Botulinum Toxin Type A, Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Cerebral Palsy (CP), Spasticity Due to Cerebral Palsy
Effect of Botulinum Toxin Type A on Motor Function in Children With Cerebral Palsy
Project Identification and Researchers Title: "Changes in functionality and quality of life when applying the botulinum toxin type A infiltration protocol in children and adolescents with cerebral palsy of the spastic hemiparesis…
- Conditions
- Cerebral Palsy (CP), Spasticity Due to Cerebral Palsy, Hemiparesis
- Trial name
- NCT07034547
- Testing
- Botulinum toxin infiltration
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Instituto Teletón Chile
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Stroke, Spasticity as Sequela of Stroke
Radial Extracorporeal Shock Wave Therapy as an Adjunct to Botulinum Toxin Type A for Post-Stroke Lower Limb Spasticity (SOLUTION)
The goal of this pilot clinical trial is to determine whether radial extracorporeal shock wave therapy (rESWT), when used as an adjunct to ultrasound-guided botulinum toxin type A (BoNT-A) injections, can enhance the therapeutic…
- Conditions
- Stroke, Spasticity as Sequela of Stroke, Lower Limb Spasticity, Upper Motor Neuron Syndrome
- Trial name
- SOLUTION (NCT07875868)
- Testing
- Radial shock Wave therapy (3000 pulses, 5 Hz, 2.5 bar)., Ultrasound-guided abobotulinumtoxin A
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Parc de Salut Mar
Scar Keloid, Hypertrophic Scar
Botulinum Toxins Intralesional Injection for Scar Pain
Botulinum toxins has been approved by the FDA to treat chronic migraine. Botox had been shown to inhibiting the release of inflammatory mediators and peripheral neurotransmitters from sensory nerve to treat neuropathic pain.
- Trial name
- NCT03982862
- Testing
- Triamcinolone, Lidocaine, Botulinum toxin A
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Kaohsiung Medical University
Sleep Bruxism, Adult
Bruxism Xeomin® Intervention Trial
The purpose of this study is to test whether severe masticatory muscle spasms during sleep (e.g. teeth clenching and grinding, known as "bruxism" in technical jargon) demonstrably decrease after application of botulinum toxin…
- Trial name
- BRUX-XIT (NCT04792398)
- Testing
- Incobotulinumtoxin A (BTX A) Xeomin®
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Dominik Ettlin
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
The purpose of this study is to determine whether injections with increasing doses (up to 800 units) of Botulinum toxin type A into muscles of the leg and/or arm are safe and effective in treating patients with spasticity on one…
- Trial name
- NCT01603459
- Testing
- IncobotulinumtoxinA
- Where
- 33 sites in United States, Canada and 6 more
- Volunteers
- 155 people
- Sponsor
- Merz Pharmaceuticals GmbH
Stroke, Hemiplegia, Spastic
The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity
There are few studies on whether botulinum toxin treatment and extracorporeal shock wave therapy are more effective than botulinum toxin alone treatment for post-stroke spasticity.
- Conditions
- Stroke, Hemiplegia, Spastic, Muscle Spasticity
- Trial name
- NCT05889026
- Testing
- Extracorporeal shock wave therapy, Botulinum toxin treatment
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Korea University Guro Hospital
Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder
This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as…
- Trial name
- BOREAL (NCT02673047)
- Testing
- botulinum toxin Type A
- Where
- 50 sites in France
- Volunteers
- 474 people
- Sponsor
- Allergan
Urinary Urge Incontinence
Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Non-neurogenic urinary urge incontinence (UUI) is a common quality of life disorder that causes people to feel an "urgent" need to urinate.
- Trial name
- NCT01226706
- Testing
- Botulinum Toxins, Type A
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Saskatchewan Health Authority - Regina Area